Preclinical Evaluation of Carfilzomib for Infant KMT2A-Rearranged Acute Lymphoblastic Leukemia

Preclinical Evaluation of Carfilzomib for Infant KMT2A-Rearranged Acute Lymphoblastic Leukemia

BackgroundInfants with KMT2A-rearranged B-cell precursor acute lymphoblastic leukemia (ALL) have poor outcomes. There is an urgent need to identify novel agents to improve survival. Proteasome inhibition has emerged as a promising therapeutic strategy for several hematological malignancies. The aim...

Full description

Bibliographic Details
Main Authors: Laurence C. Cheung, Rebecca de Kraa, Joyce Oommen, Grace-Alyssa Chua, Sajla Singh, Anastasia M. Hughes, Emanuela Ferrari, Jette Ford, Sung K. Chiu, Ronald W. Stam, Ursula R. Kees, Sébastien Malinge, Rishi S. Kotecha
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-04-01
Series:Frontiers in Oncology
Subjects:
infant
acute lymphoblastic leukemia
KMT2A
MLL
carfilzomib
PER cell lines
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.631594/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.631594/full

Similar Items